Klimiuk Paweł, Łopuszyński Wojciech, Bulak Kamila, Brzana Adam
Veterinary Diagnostic Laboratory VetDiagnostyka, 20-418 Lublin, Poland.
Sub-Department of Pathomorphology and Forensic Veterinary Medicine, Department and Clinic of Animal Internal Diseases, University of Life Sciences in Lublin, 20-601 Lublin, Poland.
Animals (Basel). 2021 Apr 20;11(4):1183. doi: 10.3390/ani11041183.
Different types of canine lymphoma respond differently to chemotherapy and have different prognoses. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in dogs. Topoisomerase II alpha (TOPIIα) protein has been shown to be a proliferation marker associated with prognostic significance. The aim of the study was to determine the relationship between TOPIIα expression, mitotic count (MC), and Ki67 antigen index in DLBCL in dogs, taking into account the applicability of these parameters to select the chemotherapy protocol with emphasis on the use of anthracycline drugs. Samples of formalin-fixed paraffin-embedded lymph nodes from 34 dogs with DLBCL were immunohistochemically labelled with anti-TOPIIα and Ki67. The number of positive cells and the intensity of the reaction were taken into account in order to assess TOPIIα expression. MC was estimated in the hematoxylin and eosin-stained slides in the area of 2.37 mm. Positive association between TOPIIα and MC, but no association between TOPIIα and Ki67 was found. It can be concluded that the immunohistochemical determination of TOPIIα as a molecular target for drugs from the anthracycline group may be used in association with MC to establish a diagnostic-clinical protocol for selecting dogs with DLBCL for treatment with anthracycline drugs.
不同类型的犬淋巴瘤对化疗的反应不同，预后也不同。弥漫性大B细胞淋巴瘤（DLBCL）是犬类中最常见的淋巴瘤。拓扑异构酶IIα（TOPIIα）蛋白已被证明是一种具有预后意义的增殖标志物。本研究的目的是确定犬DLBCL中TOPIIα表达、有丝分裂计数（MC）和Ki67抗原指数之间的关系，同时考虑这些参数在选择化疗方案（重点是使用蒽环类药物）中的适用性。对34只患有DLBCL的犬的福尔马林固定石蜡包埋淋巴结样本进行免疫组织化学标记，使用抗TOPIIα和Ki67抗体。评估TOPIIα表达时考虑阳性细胞数量和反应强度。在苏木精和伊红染色的切片中，在2.37平方毫米的区域内估计MC。发现TOPIIα与MC呈正相关，但TOPIIα与Ki67之间无相关性。可以得出结论，将TOPIIα作为蒽环类药物分子靶点的免疫组织化学测定可与MC联合使用，以建立一个诊断临床方案，用于选择患有DLBCL的犬接受蒽环类药物治疗。
